Latest News

Why Pembina Pipeline is on investors’ radar today Pembina Pipeline (TSX:PPL) has caught investor attention after a strong run over the past 3 years, with a total return of 61.7%, alongside annual revenue of CA$7,778.0m and net income of CA$1,550.0m. See our latest analysis for Pembina Pipeline. The recent move in Pembina Pipeline’s share price, including a 21.7% 3 month share price return and 16.9% year to date share price return at about CA$61.9, builds on a longer run of strong total...

Toast (TOST) just announced a partnership with Ike’s Love & Sandwiches to deploy its enterprise technology suite across 100 locations, a fresh data point for anyone tracking the company’s push with larger restaurant groups. See our latest analysis for Toast. The Ike’s rollout lands while Toast’s share price has a 90 day share price return of 28.43% decline and a year to date share price return of 22.96% decline. However, the 3 year total shareholder return of 47.66% still reflects earlier...

New York Times (NYT) is drawing fresh investor attention after outlining plans to grow digital subscriptions, broaden multimedia offerings like audio and podcasts, and sharpen digital advertising through data driven formats and new partnerships. See our latest analysis for New York Times. Those digital moves come as the share price trades at US$84.71, with a 30 day share price return of 4.83% and a 90 day share price return of 18.23%, while the 1 year total shareholder return of 77.17% and 3...

If you are wondering whether PayPay's current share price reflects its true worth, this breakdown will help you size up what you are actually paying for. After closing at US$20.36, the stock has seen a 3.6% decline over the last 7 days while still showing a 12.1% gain year to date, which can change how investors see both risk and opportunity. Recent coverage around PayPay has focused on its position in the diversified financials space and how its business profile fits into broader market...

Warren Buffett has acknowledged regret over selling part of Berkshire Hathaway's Apple stake and indicated interest in adding to the position if pricing becomes attractive again. The comments come after Buffett stepped down as CEO, offering a rare look at how Berkshire's investment thinking may evolve under the new leadership structure. Apple remains one of Berkshire Hathaway's most influential holdings, so any future move in the position could be closely watched by investors. Berkshire...

Taysha Gene Therapies recently reported that the FDA cleared it to begin the ASPIRE clinical trial of TSHA-102, its investigational gene therapy for Rett syndrome, and also granted inducement RSUs and stock options to four new employees under Nasdaq Listing Rule 5635(c)(4). This regulatory milestone for TSHA-102, coupled with preparations for potential commercialization, highlights how central Rett syndrome has become to Taysha’s business focus. Next, we’ll examine how FDA clearance to...

Wondering if Cirrus Logic at around US$154.82 is giving you fair value or asking too much for its growth story? This article breaks that question down in plain terms. The stock has shown strong recent returns, with 5.2% over 7 days, 15.6% over 30 days, 29.4% year to date, 71.6% over 1 year, 73.4% over 3 years, and 84.2% over 5 years, which naturally raises questions about how much optimism is already in the price. Recent coverage has focused on Cirrus Logic as part of wider discussions...

Aon recently expanded its digital infrastructure capabilities by appointing Stephen Fox as Managing Director and, earlier, upgraded its Radford McLagan Compensation Database with AI-specific job families and tools to better assess fast-evolving AI roles worldwide. Together, these moves show Aon deepening its role at the intersection of risk, capital, and AI-enabled workforce planning for large-scale, technology-focused clients. Now we’ll examine how Aon’s AI-focused compensation enhancements...

If you are wondering whether DoubleVerify Holdings is attractively priced or still too expensive, this breakdown will help you frame the current share price against what you might actually be paying for. The stock last closed at US$10.09, with returns of 3.2% over the past week, a 6.6% decline over the past month, and a 24.5% decline over the past year, which may have changed how the market is viewing its risk and reward trade off. Recent coverage has focused on DoubleVerify Holdings as an...

In early April 2026, Applied Materials introduced two chipmaking systems for 2nm and Angstrom-era logic chips that use atomic-level deposition to improve transistor isolation and metal gate formation for advanced AI processors. By solving key manufacturing bottlenecks in Gate-All-Around transistor structures and already seeing adoption by leading foundries, these tools deepen Applied Materials’ role at the core of next-generation AI chip production. Next, we’ll examine how this push into...

On March 16, 2026, McGill and Partners announced a collaboration with American International Group to apply agentic artificial intelligence to manage capacity deployment in the subscription market, supported by AIG’s US$1.60 billion commitment to McGill’s specialty gross premiums written portfolio, representing 25% of AIG’s capacity. This partnership highlights how AIG is tying advanced AI tools directly to underwriting decisions and capital allocation, potentially reshaping how it...

In early April 2026, Bank of Montreal announced and completed multiple callable senior fixed-rate note offerings across North American and international markets, while also unveiling plans for tokenized cash settlement with CME Group and Google Cloud and launching an institute focused on applied AI and quantum research. Together, these funding moves and technology initiatives point to Bank of Montreal positioning itself as both a capital markets funding hub and an early adopter of digital...

Wondering whether Vistra at around US$155.89 still offers value or if most of the opportunity is already priced in? This breakdown helps you size that up with numbers rather than hype. The stock price has moved 1.3% over the last 7 days, while the 30 day and year to date returns of a 4.7% decline and 5.7% decline sit against a 32.8% gain over the past year and a very large 3 year and 5 year return profile. Recent coverage has focused on Vistra as a major US utilities player, with attention...

In recent days, commentary around the Pacer Data & Infrastructure Real Estate ETF and Jefferies’ views on SBA Communications has highlighted American Tower’s long history of consistent dividend increases, stable long-term tower leases and comparatively strong platform quality within the infrastructure REIT space. Amid questions over competitors’ leverage, dividend cuts and potential sale processes, American Tower is being framed as a relatively dependable income and infrastructure exposure...

Vertex Pharmaceuticals (VRTX) just received U.S. FDA approval to expand the use of its cystic fibrosis drugs ALYFTREK and TRIKAFTA. This regulatory milestone widens treatment eligibility and puts the stock back in focus for many investors. See our latest analysis for Vertex Pharmaceuticals. The FDA label expansions arrive after a softer run in the share price, with a 90 day share price return of a 5.48% decline and a 1 year total shareholder return of a 7.96% decline. However, a 5 year total...

Investors may be wondering if Madrigal Pharmaceuticals at around US$519.75 a share is still offering value, or if the easy gains are already behind it. The stock has been volatile recently, with a 1.9% decline over the last week, a 20.0% return over 30 days, a 12.5% decline year to date, and a 65.6% return over the past year, alongside very large gains over 5 years. Recent headlines around Madrigal have focused on its position in the biotech space and the market's shifting expectations for...

Even if it's not a huge purchase, we think it was good to see that John Holliday, the Independent Non-Executive...

In late March 2026, Oklo Inc. and Sweden’s Blykalla AB expanded their transatlantic partnership to collaborate on fast reactor commercialization, with Blykalla planning US$100–200 million of potential U.S. investments and committing 30–40 engineers to support Oklo’s DOE‑authorized reactor pilot and related technical workstreams. This deeper collaboration not only aims to speed Oklo’s technology development and enable fast‑neutron irradiation testing, but also highlights how external capital...

Why Robertet (ENXTPA:RBT) is in Focus Ahead of Earnings Robertet (ENXTPA:RBT) is drawing extra attention after a 2.48% gain into its upcoming earnings announcement, with investors watching closely for guidance on earnings per share, operating margins, and raw material cost trends. See our latest analysis for Robertet. That pre earnings move sits against a softer backdrop, with a 90 day share price return of 6.38% decline and year to date share price return of 6.48% decline, while the 1 year...

Seven Democratic U.S. senators have launched a federal investigation into an IRS tax credit payout to Cheniere Energy related to its LNG export vessels. The probe questions whether Cheniere properly qualified for alternative fuel tax credits and how those credits were applied. The outcome could influence how tax rules are interpreted for LNG infrastructure and similar energy projects. For investors watching Cheniere Energy (NYSE:LNG), the scrutiny comes as the stock trades at $275.21, with...

Recent news highlights Kinder Morgan’s past record net income and adjusted EBITDA, a roughly US$10.00 billion, mostly natural gas‑focused project backlog, and highly fee-based or hedged cash flows that are drawing attention ahead of its upcoming earnings report. Investors are especially focused on how Kinder Morgan’s large, long-term contracted natural gas infrastructure tied to power generation and LNG exports could underpin its cash flow stability as analyst earnings estimates...

If you are wondering whether Kratos Defense & Security Solutions is still good value after a strong run, this article breaks down what the current share price might be implying about the company. The stock last closed at US$74.46, with returns of 10.6% over 7 days, a 16.3% decline over 30 days, a 6.1% decline year to date, and a 1 year return of 134.8%, alongside a 3 year return of 468.8% and a 5 year return of 164.5%. These moves sit against a backdrop of ongoing investor attention on...

Recent performance snapshot DraftKings (DKNG) has seen mixed share performance recently, with a roughly 4.3% move over the past day and an 8.0% gain over the past week, contrasting with weaker returns over the past month and the past 3 months. See our latest analysis for DraftKings. The recent 1-day share price return of 4.31% and 7-day gain of 8.03% come after a much weaker 90-day share price return of a 33.46% decline and a 1-year total shareholder return of a 33.20% decline, suggesting...

Lendlease Global Commercial REIT recently entered into senior unsecured sustainability-linked term and revolving credit facilities of up to S$500 million to support its sustainable growth objectives. This move deepens the REIT’s use of sustainability-linked financing, tying its access to capital more closely to environmental and social performance goals. We’ll now examine how this new sustainability-linked funding capacity shapes Lendlease Global Commercial REIT’s investment narrative and...